[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573325":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":48,"collaborators":50,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":20,"eligibilityCriteria":59,"healthyVolunteers":56,"sex":60,"minAge":61,"maxAge":20,"enrollmentInfo":62,"targetDuration":20,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":20,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment with Qutenza Patch (Topical Capsaicin)","EXPERIMENTAL","Up to 4 topical capsaicin patches will be applied on your feet for 30 minutes.",[13],"Drug: Qutenza Patch",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Qutenza Patch","Given topical",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Saba Javed, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","713-792-9530","sjaved@mdanderson.org",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"MD Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-95.36327,29.76328,{"lat":43,"lon":42},[46,47],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":49,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[51],{"name":52,"class":53},"Averitas Pharma, Inc.","INDUSTRY","100573325","early-phase-1-exploring-the-benefit-of-topical-capsaicin-in-treating-pain-from-chemo-induced-peripheral-neuropathy-a-longitudinal-single-center-pilot-study-100573325",false,"NCT06744816","Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study","Inclusion Criteria:\n\n* Participants diagnosed with pain of the lower extremity from chronic (\\>90 days duration) CIPN (due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds), seen at MD Anderson Cancer Center\n* Participants reporting baseline pain ≥ 4 (0-10 scale, NRS)\n* Participants age 18+\n* Participants who have completed chemotherapy within the last year at the time of enrollment.\n\nExclusion Criteria:\n\n* Participants with cognitive dysfunction\n* Participants with recent history (\\\u003C6 months) of drug or alcohol abuse\n* Participants with open skin lesion or undergoing antibiotic therapy for local for systemic infection\n* Participants with allergies to capsaicin or adhesives\n* Pregnant participants","ALL","18 Years",{"count":63,"type":64},20,"ESTIMATED","INTERVENTIONAL",[67],"EARLY_PHASE1","To learn if topical capsaicin can help relieve pain from CIPN and improve gait (the pattern of walking) in patients.",[70],"Peripheral Neuropathy Due to Chemotherapy","2026-06-23",{"date":73,"type":74},"2026-06-26","ACTUAL",{"date":76,"type":74},"2025-12-11",{"date":78,"type":64},"2027-11-30",{"name":5,"class":6},1]